Explore why rare HER2-mutant NSCLC is highly aggressive and how broad NGS testing helps identify candidates for new HER2-targeted treatments.
Targeted Therapy in HER2+ NSCLC
New FDA-approved zongepanib boosts responses in HER2-mutant lung cancer, delivering durable control with fewer side effects than standard chemo.
FDA‑approved zongertinib transforms HER2‑mutant NSCLC, delivering ~77% responses with less toxicity than chemo.
Zongertinib shows 77% frontline responses and 96% disease control, with rapid onset and promising durability versus other HER2 TKIs.
New data show zongertinib is well tolerated in frontline lung cancer, with manageable diarrhea, minimal rash, and low ILD risk.
Zongertinib shows strong tolerability in frontline lung cancer cohort, with mostly mild diarrhea, minimal rash, low ILD, and few dose stops.